Pegylated darbepoetin beta - Biocad

Drug Profile

Pegylated darbepoetin beta - Biocad

Alternative Names: BCD-131; PEG-Darbepoetin

Latest Information Update: 19 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biocad
  • Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaemia

Most Recent Events

  • 19 Jul 2016 Phase-I clinical trials in Anaemia in Russia (SC) (Biocad pipeline, July 2016)
  • 06 Apr 2016 Biocad plans a phase I trial in Healthy volunteers Russia (SC and IV) (NCT02731469)
  • 01 Apr 2016 Preclinical trials in Anaemia in Russia (Parenteral) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top